insights_auto
Why is ABVX down 17,21%?
Dive Deeperchevron_right
ABVX:EPA
Abivax SA
63,00 €
arrow_downward
-17,21%(-13,10) 1D
20 նոյ, 17:38:58 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
74,50 €
High
74,50 €
Low
59,30 €
Mkt. cap
5,57 մլրդ
Avg. vol.
112,96 հզր
Volume
842,42 հզր
52-wk high
139,00 €
52-wk low
59,30 €
EPS
-5,20 €
Shares outstanding
87,55 մլն
No. of employees
98
Open
74,50 €
High
74,50 €
Low
59,30 €
Mkt. cap
5,57 մլրդ
Avg. vol.
112,96 հզր
Volume
842,42 հզր
52-wk high
139,00 €
52-wk low
59,30 €
EPS
-5,20 €
Shares outstanding
87,55 մլն
No. of employees
98
News stories
From web sources and news partners
Yahoo Finance
·
20 ժամ առաջ
Abivax (ENXTPA:ABVX) Stock Could Be A Bargain On Cash Flow
Briefs Finance
·
1 օր առաջ
Abivax Shares Fall After Short Seller Labels Drug Toxic
TOKENPOST
·
1 օր առաջ
Abivax Shares Fall About 9% After Scorpion Research Short Report
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 թ. դեկ 4
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com